Alexis F. Guédon

MD, MPH, PhD student - Vascular medicine specialist / CCU-AH @HopSaintAntoine / Clinical epidemiology @Sorbonne_Univ_ / EAS Young Fellow @society_eas

[Alexis F. Guédon @alguedon]

I was very happy to present our work during the #ESC2022 : elevated Lp(a) level is associated with Major Adverse Limb Event ! Many thanks to the session moderators #ESCCongress #PAD #lpa @esccardio @TristanMirault @gdetricheMD @GoudotG @jbdefrem @Marcodecarlo72 @MarcBonaca

[Circulation @CircAHA]

Does tocilizumab lower cardiovascular risk in giant cell arteritis? New observational data presented at #ESCCongress + sim pub: target trial emulation of 1,997 pts found 2-yr MACE 6.4% vs 10.7% with methotrexate. https://t.co/bVvnLfeRv8 @alguedon

[RMD Open @bmj_rmdopen]

🦴 Giant cell arteritis & Clonal hematopoiesis (CH) —somatic mutations in HSCs

👥 55.1% of patients with GCA had CH
🔬 TET2 & JAK2 mutations in #GCA ➡️ Relapse & poor outcomes.
👉 Screening for CH may guide tailored therapies.

🔓https://t.co/MHoGaFDJ7S

@alguedon

[Marios Georgakis @MariosGeorgakis]

Colchicine is the first anti-inflammatory drug approved for athero-CVD prevention

#CONVINCE tested colchicine in ischemic stroke🧠

The results were presented at #ESOC2024 by Peter Kelly @ESOstroke
https://t.co/DsvIR0B5m1

The primary endpoint was negative. A🧵with some thoughts

[Alexis F. Guédon @alguedon]

@GendronNico @isth @GattAlexander @VirginiaHdezGea @CukerMd @DebSiegal @SimonStanworth @LaraNRoberts1 Congrats !! 👏👏

[Nicolas Gendron @GendronNico]

🚨Anticoagulation for stroke prevention in AF and Treatment of VTE and Portal Vein Thrombosis in Cirrhosis: Guidance @ISTH

👏Congrats @GattAlexander @VirginiaHdezGea @CukerMd @DebSiegal @SimonStanworth @LaraNRoberts1
🙏Honored to have been a part of this

https://t.co/qBuPMnOlDs

[azin kheirkhah @azinkh96]

I had such a great time at the #EASCongress! Thanks to the #EASYoungFellows programme I was able to gain so many new experiences and expand my network. Hope to see you all again soon and thanks to everyone who made it such a fabulous congress! #EASCongress2024 #MyEAS2024 #EAS

[Alexis F. Guédon @alguedon]

@Sorbonne_Univ_ @MSaintantoine @HopSaintAntoine

[Alexis F. Guédon @alguedon]

I was very happy to present our results from the SPARCL cohort about the association between low ApoE levels and higher incidence of cerebrovascular events at the 2024 @EASCongress ! @society_eas @lasfmv @NSFAthero @GoudotG @gdetricheMD @jbdefrem

[Borge G Nordestgaard @BNordestgaard]

3 papers in NEJM published simultaneously with presentations by Christie Ballantyne and Bob Rosenson at the European Atherosclerosis Society Congress in Lyon France - documenting huge reductions in remnant cholesterol after siRNA inhibition of ApoC3 and ANGTPL3

[Emma M. Groarke @emmamgroarke]

Also wanted to add, here is the free share link for anyone who needs access:

https://t.co/dPP9aZWPN3

[Alexis F. Guédon @alguedon]

I was very honored to provide my commentary for the @BloodJournal on the very nice paper about thrombosis and VEXAS by the fantastic @emmamgroarke team !

[Emma M. Groarke @emmamgroarke]

Check out the commentary on our #VEXAS article in @BloodJournal

[Emma M. Groarke @emmamgroarke]

Check out the commentary on our #VEXAS article in @BloodJournal

[Arsene Mekinian @mekinian2]

https://t.co/0o6d792NHl

[Alexis F. Guédon @alguedon]

@Dellal2017 @mekinian2 Merci beaucoup !

[NEJM @NEJM]

Presented at #ERA24:

FLOW trial: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function. https://t.co/Q9DAA6mPte

[Heather L Gornik @heatherlgornik]

The multi societal #PAD guideline in print at long last… Amazing things can happen when specialties work together, review the evidence, and put the patient at the center. Hats off to a most collaborative writing committee. @herbaronowMD @DartmthSurgHSR @schuyler_jones

[AHA Science @AHAScience]

1/ Published today: The updated evidence-based recommendations for managing Lower Extremity PAD, originally outlined in the 2016 Guideline, now incorporate the latest research findings to assist clinicians.

✍🏽:@heatherlgornik

📖: @CircAHA

[Julien Kirchgesner @J_Kirchgesner]

3⃣rd edition of the 4EU+PharmacoEpi course with #PharmacoEpi students from all over Europe at @UniHeidelberg ! Great discussion on multi-database studies. Stay tuned for next edition in Jan 2025 ! @4EUplusAlliance

https://t.co/D8PQ1OwoCt

[Nicolas Gendron @GendronNico]

📰 Our review is online @ThrombosisRese1 discussing risk factors during the acute phase of DVT that are associated with the development of PTS ⚡️🦵

👏Bravo @lina_2411 !

@PlanquetteSante @DavidMSmadja @GoudotG @SanchezOlivie11 @MedVasc_HEGP
@INNOVTE1
https://t.co/04eOrP9VZy

[Julien Kirchgesner @J_Kirchgesner]

The 3rd edition of the 4EU+PharmacoEpi course has just started with 22 students from 5 EU universities ! A new extended edition supporting an integrative educational 🇪🇺 program in pharmacoepidemiology in the @4EUplusAlliance